OncoMatch/Lymphoma — Diffuse Large B-Cell (DLBCL)/BCL2 rearrangement
Lymphoma — Diffuse Large B-Cell (DLBCL)BCL2 rearrangement Clinical Trials
BCL2 rearrangements occur in approximately 20–30% of DLBCL and, in double-hit configuration with MYC, define a high-grade aggressive subtype. Venetoclax, a BCL2 inhibitor approved in CLL/AML, has been studied in BCL2-overexpressing DLBCL with variable results. Trials investigate venetoclax combinations with rituximab-based regimens, novel BCL2 inhibitors, and BCL2/BCL-XL dual inhibitors in BCL2-rearranged or BCL2-overexpressing DLBCL.
Top recruiting BCL2 rearrangement Lymphoma — Diffuse Large B-Cell (DLBCL) trials
Ranked by phase and US site count. See all 12 trials matched to your profile →
A Randomized, Multicenter, Phase III Trial Comparing Treatment With R-mini-CHOP With R-mini-CHP + Polatuzumab Vedotin in Patients With Diffuse Large Cell B Cell Lymphoma
Nordic Lymphoma Group
Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma
National Cancer Institute (NCI)
A Study of Circulating Tumor DNA (ctDNA) Testing for People With B-Cell Lymphoma
Memorial Sloan Kettering Cancer Center
Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia
Mayo Clinic
Acalabrutinib Maintenance for the Treatment of Patients With Large B-cell Lymphoma
Jonsson Comprehensive Cancer Center
CNS-Relapse Prevention in High-Risk Diffuse Large B-cell Lymphoma With Thiotepa-based Autologous Stem Cell Transplant
Washington University School of Medicine
Browse other molecular targets with active Lymphoma — Diffuse Large B-Cell (DLBCL) trials.